You are here

Adempas (Riociguat; Bayer/Merck & Co) Drug Overview & Product Profiles 2016-2025

DUBLIN, July 8, 2019 /PRNewswire/ -- The "Adempas" report has been added to's offering.

Drug Overview

Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells. In pulmonary hypertension, the production of nitric oxide is reduced; Adempas directly stimulates sGC's enzymatic activity and increases the enzymes' sensitivity to nitric oxide, leading to increased vasodilation of the pulmonary arteries.

Analyst Outlook

Adempas (riociguat; Bayer/Merck & Co) is the only drug approved for both pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), after completing separate pivotal clinical trials in both indications. Despite being approved for an underserved patient population, Adempas's sales have not reflected this opportunity. A contributing factor may be the high rates of off-label use across the treatment paradigm.

Furthermore, the author perceives that the wider market trend towards combination use will continue to inadvertently push Adempas aside in the treatment algorithm, as the drug is contraindicated for use in combination with phosphodiesterase 5 (PDE5) inhibitors.

Thus, Bayer and Merck & Co may rely on trials that position Adempas as an alternative treatment for those with inadequate responses to PDE5 inhibitors. The companies would do well to evaluate Adempas's use for CTEPH in combination with Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) to capitalize on this trend and to leverage the potential threat of competition from Opsumit for CTEPH into an opportunity.

Key Topics Covered:


Drug Overview

Product Profiles

Adempas : Pulmonary hypertension


Figure 1: Adempas for pulmonary hypertension - SWOT analysis

Figure 2: The authors drug assessment summary of Adempas for pulmonary hypertension

Figure 3: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016-25


Table 1: Adempas drug profile

Table 2: Adempas pivotal trial data in pulmonary hypertension

Table 3: Adempas late-phase trial data in pulmonary arterial hypertension

Table 4: Adempas ongoing late-phase trials

Table 5: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets